News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ZS Pharma (ZSPH) Announces Closing Of Initial Public Offering And Full Exercise Of Underwriters’ Over-Allotment Option


6/24/2014 10:37:02 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

COPPELL, Texas--(BUSINESS WIRE)--ZS Pharma, Inc., a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced the closing of its initial public offering of 6,836,111 shares of common stock at a public offering price of $18.00 per share. This includes the exercise in full by the underwriters of their option to purchase up to 891,667 additional shares of common stock. The net proceeds from the sale of shares, after deducting underwriting discounts, commissions and other estimated offering expenses, will be approximately $112 million.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
ZS Pharma
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES